{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:25:47Z","timestamp":1780467947929,"version":"3.54.1"},"reference-count":108,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/100009377","name":"Key Project of the Education Department of Hunan Province","doi-asserted-by":"publisher","award":["18A241"],"award-info":[{"award-number":["18A241"]}],"id":[{"id":"10.13039\/100009377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan province","doi-asserted-by":"publisher","award":["2018JJ2343"],"award-info":[{"award-number":["2018JJ2343"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770454"],"award-info":[{"award-number":["81770454"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title\/><jats:p>Coronary heart disease (CHD) is closely related to hypercholesterolemia, and lowering serum cholesterol is currently the most important strategy in reducing CHD. In humans, the serum cholesterol level is determined mainly by three metabolic pathways, namely, dietary cholesterol intake, cholesterol synthesis, and cholesterol degradation in vivo. An intervention that targets the key molecules in the three pathways is an important strategy in lowering serum lipids. Statins inhibit 3-hydroxyl-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) to reduce low-density lipoprotein (LDL) by about 20% to 45%. However, up to 15% of patients cannot tolerate the potential side effects of high statin dosages, and several patients also still do not reach their optimal LDL goals after being treated with statins. Ezetimibe inhibits cholesterol absorption by targeting the Niemann\u2013Pick C1-like 1 protein (NPC1L1), which is related to cholesterol absorption in the intestines. Ezetimibe lowers LDL by about 18% when used alone and by an additional 25% when combined with statin therapy. The proprotein convertase subtilisin\/kexin type 9 (PCSK9) increases hepatic LDLR degradation, thereby reducing the liver\u2019s ability to remove LDL, which can lead to hypercholesterolemia. Evolocumab, which is a PCSK9 monoclonal antibody, can reduce LDL from baseline by 53% to 56%. The three drugs exert lipid-lowering effects by regulating the three key pathways in lipid metabolism. Combining any with the two other drugs on the basis of statin treatment has improved the lipid-lowering effect. Whether the combination of the three musketeers will reduce the side effects of monotherapy and achieve the lipid-lowering effect should be studied further in the future.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867327666200505091738","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T13:20:12Z","timestamp":1588684812000},"page":"1025-1041","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-6751","authenticated-orcid":true,"given":"Qian","family":"Xu","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-2734","authenticated-orcid":true,"given":"Yiming","family":"Deng","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5621-840X","authenticated-orcid":true,"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-2551","authenticated-orcid":true,"given":"Xiangrui","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3756-4953","authenticated-orcid":true,"given":"Min","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-7354","authenticated-orcid":true,"given":"Zhong","family":"Ren","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-3054","authenticated-orcid":true,"given":"Juan","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-2855","authenticated-orcid":true,"given":"Yaling","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-3491","authenticated-orcid":true,"given":"Zhisheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-4635","authenticated-orcid":true,"given":"Zhihan","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9483-5356","authenticated-orcid":true,"given":"Lushan","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan 421001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","volume":"349","author":"Murray C.J.L.","year":"1997","unstructured":"Murray C.J.L.; Lopez A.D.; Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997,349(9061),1269-1276","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/eurheartj\/ehu469","volume":"36","author":"Niccoli G.","year":"2015","unstructured":"Niccoli G.; Scalone G.; Crea F.; Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J 2015,36(8),475-481","journal-title":"Eur Heart J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4093\/dmj.2013.37.6.433","volume":"37","author":"Roh E.","year":"2013","unstructured":"Roh E.; Ko S-H.; Kwon H-S.; Kim N.H.; Kim J.H.; Kim C.S.; Song K-H.; Won J.C.; Kim D.J.; Choi S.H.; Lim S.; Cha B-Y.; Taskforce team of diabetes fact sheet of the Korean Diabetes Association. Prevalence and management of dyslipidemia in Korea: Korea national health and nutrition examination survey during 1998 to 2010. Diabetes Metab J 2013,37(6),433-449","journal-title":"Diabetes Metab J"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","volume":"19","author":"Robinson J.G.","year":"2013","unstructured":"Robinson J.G.; Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association expert panel on familial hypercholesterolemia. J Manag Care Pharm 2013,19(2),139-149","journal-title":"J Manag Care Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"Cohen J.C.","year":"2006","unstructured":"Cohen J.C.; Boerwinkle E.; Mosley T.H.; Jr.; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006,354(12),1264-1272","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1194\/jlr.M089201","volume":"59","author":"Nihei W.","year":"2018","unstructured":"Nihei W.; Nagafuku M.; Hayamizu H.; Odagiri Y.; Tamura Y.; Kikuchi Y.; Veillon L.; Kanoh H.; Inamori K.I.; Arai K.; Kabayama K.; Fukase K.; Inokuchi J.I.; NPC1L1-dependent intestinal cholesterol absorption requires ganglioside GM3 in membrane microdomains. J Lipid Res 2018,59(11),2181-2187","journal-title":"J Lipid Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","volume":"77","author":"Alberts A.W.","year":"1980","unstructured":"Alberts A.W.; Chen J.; Kuron G.; Hunt V.; Huff J.; Hoffman C.; Rothrock J.; Lopez M.; Joshua H.; Harris E.; Patchett A.; Monaghan R.; Currie S.; Stapley E.; Albers-Schonberg G.; Hensens O.; Hirshfield J.; Hoogsteen K.; Liesch J.; Springer J.; Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980,77(7),3957-3961","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1073\/pnas.0400441101","volume":"101","author":"Smart E.J.","year":"2004","unstructured":"Smart E.J.; De Rose R.A.; Farber S.A.; Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc Natl Acad Sci USA 2004,101(10),3450-3455","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"Dias C.S.","year":"2012","unstructured":"Dias C.S.; Shaywitz A.J.; Wasserman S.M.; Smith B.P.; Gao B.; Stolman D.S.; Crispino C.P.; Smirnakis K.V.; Emery M.G.; Colbert A.; Gibbs J.P.; Retter M.W.; Cooke B.P.; Uy S.T.; Matson M.; Stein E.A.; Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012,60(19),1888-1898","journal-title":"J Am Coll Cardiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","volume":"72","author":"Endo A.","year":"1976","unstructured":"Endo A.; Kuroda M.; Tanzawa K.; Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976,72(2),323-326","journal-title":"FEBS Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1073\/pnas.85.14.5264","volume":"85","author":"Singer I.I.","year":"1988","unstructured":"Singer I.I.; Scott S.; Kazazis D.M.; Huff J.W.; Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc Natl Acad Sci USA 1988,85(14),5264-5268","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R600009-JLR200","volume":"47","author":"Steinberg D.","year":"2006","unstructured":"Steinberg D.; Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 2006,47(7),1339-1351","journal-title":"J Lipid Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","volume":"161","author":"Goldstein J.L.","year":"2015","unstructured":"Goldstein J.L.; Brown M.S.; A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015,161(1),161-172","journal-title":"Cell"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/13543776.2016.1216977","volume":"26","author":"Oliveira E.F.","year":"2016","unstructured":"Oliveira E.F.; Santos-Martins D.; Ribeiro A.M.; Br\u00e1s N.F.; Cerqueira N.S.; Sousa S.F.; Ramos M.J.; Fernandes P.A.; HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015). Expert Opin Ther Pat 2016,26(11),1257-1272","journal-title":"Expert Opin Ther Pat"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1021\/jm00096a015","volume":"35","author":"Bone E.A.","year":"1992","unstructured":"Bone E.A.; Davidson A.H.; Lewis C.N.; Todd R.S.; Synthesis and biological evaluation of dihydroeptastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem 1992,35(18),3388-3393","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/jm00155a040","volume":"29","author":"Hoffman W.F.","year":"1986","unstructured":"Hoffman W.F.; Alberts A.W.; Anderson P.S.; Chen J.S.; Smith R.L.; Willard A.K.; 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J Med Chem 1986,29(5),849-852","journal-title":"J Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1021\/jm00075a024","volume":"36","author":"Connolly P.J.","year":"1993","unstructured":"Connolly P.J.; Westin C.D.; Loughney D.A.; Minor L.K.; HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts. J Med Chem 1993,36(23),3674-3685","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6468(08)70080-8","volume":"40","author":"Roth B.D.","year":"2002","unstructured":"Roth B.D.; The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog Med Chem 2002,40,1-22","journal-title":"Prog Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.bmcl.2007.11.124","volume":"18","author":"Park W.K.","year":"2008","unstructured":"Park W.K.; Kennedy R.M.; Larsen S.D.; Miller S.; Roth B.D.; Song Y.; Steinbaugh B.A.; Sun K.; Tait B.D.; Kowala M.C.; Trivedi B.K.; Auerbach B.; Askew V.; Dillon L.; Hanselman J.C.; Lin Z.; Lu G.H.; Robertson A.; Sekerke C.; Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Bioorg Med Chem Lett 2008,18(3),1151-1156","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/13543784.11.1.125","volume":"11","author":"Davidson M.H.","year":"2002","unstructured":"Davidson M.H.; Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 2002,11(1),125-141","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"Schachter M.","year":"2005","unstructured":"Schachter M.; Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005,19(1),117-125","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1042\/bst0310528","volume":"31","author":"Holdgate G.A.","year":"2003","unstructured":"Holdgate G.A.; Ward W.H.; McTaggart F.; Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003,31(Pt 3),528-531","journal-title":"Biochem Soc Trans"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1124\/mol.105.014019","volume":"68","author":"Hirano M.","year":"2005","unstructured":"Hirano M.; Maeda K.; Matsushima S.; Nozaki Y.; Kusuhara H.; Sugiyama Y.; Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005,68(3),800-807","journal-title":"Mol Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jpba.2007.09.024","volume":"46","author":"Wang S-R.","year":"2008","unstructured":"Wang S-R.; Chen Y.; Wu L-P.; Miao W-J.; Xiong M-J.; Chen C.; Zhong Z-R.; Ye L-M.; Development of predictive quantitative retention-activity relationship models of HMG-CoA reductase inhibitors by biopartitioning micellar chromatography. J Pharm Biomed Anal 2008,46(2),243-249","journal-title":"J Pharm Biomed Anal"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1067\/mhj.2002.130300","volume":"144","author":"Istvan E.S.","year":"2002","unstructured":"Istvan E.S.; Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 2002,144(6)(Suppl.),S27-S32","journal-title":"Am Heart J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/humu.1380010602","volume":"1","author":"Hobbs H.H.","year":"1992","unstructured":"Hobbs H.H.; Brown M.S.; Goldstein J.L.; Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992,1(6),445-466","journal-title":"Hum Mutat"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"Istvan E.S.","year":"2001","unstructured":"Istvan E.S.; Deisenhofer J.; Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001,292(5519),1160-1164","journal-title":"Science"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1008-1050","volume":"14","author":"Endo A.","year":"2008","unstructured":"Endo A.; A gift from nature: the birth of the statins. Nat Med 2008,14(10),1050-1052","journal-title":"Nat Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","volume":"33","author":"Endo A.","year":"1992","unstructured":"Endo A.; The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992,33(11),1569-1582","journal-title":"J Lipid Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0021-9150(79)90174-6","volume":"32","author":"Tsujita Y.","year":"1979","unstructured":"Tsujita Y.; Kuroda M.; Tanzawa K.; Kitano N.; Endo A.; Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 1979,32(3),307-313","journal-title":"Atherosclerosis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1073\/pnas.80.13.4124","volume":"80","author":"Bilheimer D.W.","year":"1983","unstructured":"Bilheimer D.W.; Grundy S.M.; Brown M.S.; Goldstein J.L.; Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983,80(13),4124-4128","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/dom.12581","volume":"18","author":"Deedwania P.C.","year":"2016","unstructured":"Deedwania P.C.; Shepherd J.; Breazna A.; De Micco D.A.; Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study. Diabetes Obes Metab Treating to New Targets (TNT) Steering Committee Investigators2016,18(1),56-63","journal-title":"Diabetes Obes Metab"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"Downs J.R.","year":"1998","unstructured":"Downs J.R.; Clearfield M.; Weis S.; Whitney E.; Shapiro D.R.; Beere P.A.; Langendorfer A.; Stein E.A.; Kruyer W.; Gotto A.M.; Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998,279(20),1615-1622","journal-title":"JAMA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever P.S.","year":"2003","unstructured":"Sever P.S.; Dahl\u00f6f B.; Poulter N.R.; Wedel H.; Beevers G.; Caulfield M.; Collins R.; Kjeldsen S.E.; Kristinsson A.; McInnes G.T.; Mehlsen J.; Nieminen M.; O\u2019Brien E.; Ostergren J.; Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet ASCOT investigators2003,361(9364),1149-1158","journal-title":"Lancet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"Asselbergs F.W.","year":"2004","unstructured":"Asselbergs F.W.; Diercks G.F.; Hillege H.L.; van Boven A.J.; Janssen W.M.; Voors A.A.; de Zeeuw D.; de Jong P.E.; van Veldhuisen D.J.; van Gilst W.H.; Prevention of renal and vascular endstage disease intervention trial (PREVEND IT) investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004,110(18),2809-2816","journal-title":"Circulation"},{"key":"ref=36","first-page":"1383","volume":"344","year":"1994","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994,344(8934),1383-1389","journal-title":"Lancet"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"Shepherd J.","year":"1995","unstructured":"Shepherd J.; Cobbe S.M.; Ford I.; Isles C.G.; Lorimer A.R.; MacFarlane P.W.; McKillop J.H.; Packard C.J.; Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med West of Scotland Coronary Prevention Study Group1995,333(20),1301-1307","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"Sacks F.M.","year":"1996","unstructured":"Sacks F.M.; Pfeffer M.A.; Moye L.A.; Rouleau J.L.; Rutherford J.D.; Cole T.G.; Brown L.; Warnica J.W.; Arnold J.M.; Wun C.C.; Davis B.R.; Braunwald E.; The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996,335(14),1001-1009","journal-title":"N Engl J Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.115.018580","volume":"133","author":"Hague W.E.","year":"2016","unstructured":"Hague W.E.; Simes J.; Kirby A.; Keech A.C.; White H.D.; Hunt D.; Nestel P.J.; Colquhoun D.M.; Pater H.; Stewart R.A.; Sullivan D.R.; Thompson P.L.; West M.; Glasziou P.P.; Tonkin A.M.; Long-term effectiveness and safety of pravastatin in patients with coronary heart disease: sixteen years of follow-up of the LIPID study. Circulation LIPID study investigators2016,133(19),1851-1860","journal-title":"Circulation"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","year":"2002","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet Heart Protection Study Collaborative Group2002,360(9326),7-22","journal-title":"Lancet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"Shepherd J.","year":"2002","unstructured":"Shepherd J.; Blauw G.J.; Murphy M.B.; Bollen E.L.; Buckley B.M.; Cobbe S.M.; Ford I.; Gaw A.; Hyland M.; Jukema J.W.; Kamper A.M.; Macfarlane P.W.; Meinders A.E.; Norrie J.; Packard C.J.; Perry I.J.; Stott D.J.; Sweeney B.J.; Twomey C.; Westendorp R.G.; Risk P.P.S.P.E.; Prospective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet PROSPER study group2002,360(9346),1623-1630","journal-title":"Lancet"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0022-2275(20)38255-9","volume":"30","author":"Mosley S.T.","year":"1989","unstructured":"Mosley S.T.; Kalinowski S.S.; Schafer B.L.; Tanaka R.D.; Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 1989,30(9),1411-1420","journal-title":"J Lipid Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/009127002401102876","volume":"42","author":"White C.M.","year":"2002","unstructured":"White C.M.; A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002,42(9),963-970","journal-title":"J Clin Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","volume":"133","author":"Ford I.","year":"2016","unstructured":"Ford I.; Murray H.; McCowan C.; Packard C.J.; Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation 2016,133(11),1073-1080","journal-title":"Circulation"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.amjcard.2005.12.042","volume":"97","author":"Nicholls S.J.","year":"2006","unstructured":"Nicholls S.J.; Tuzcu E.M.; Sipahi I.; Schoenhagen P.; Hazen S.L.; Ntanios F.; Wun C.C.; Nissen S.E.; Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006,97(11),1553-1557","journal-title":"Am J Cardiol"},{"key":"ref=46","first-page":"749","volume":"63","author":"Scheen A.J.","year":"2008","unstructured":"Scheen A.J.; [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein] Rev Med Liege 2008,63(12),749-753","journal-title":"Rev Med Liege"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","volume":"121","author":"Chan K.L.","year":"2010","unstructured":"Chan K.L.; Teo K.; Dumesnil J.G.; Ni A.; Tam J.; Investigators A.; Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation ASTRONOMER Investigators2010,121(2),306-314","journal-title":"Circulation"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.20452\/pamw.3765","volume":"126","author":"Yusuf S.","year":"2016","unstructured":"Yusuf S.; Panju A.; Jaeschke R.; HOPE- 3, BP treatment, milestones in CV prevention. Dr. Salim Yusuf in an interview with Dr. Akbar Panju and Dr Roman Jaeschke Pol Arch Med Wewn 2016,126(12),1033-1035","journal-title":"Akbar Panju and Dr Roman Jaeschke Pol Arch Med Wewn"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4330\/wjc.v7.i7.404","volume":"7","author":"DuBroff R.","year":"2015","unstructured":"DuBroff R.; de Lorgeril M.; Cholesterol confusion and statin controversy. World J Cardiol 2015,7(7),404-409","journal-title":"World J Cardiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.14423\/SMJ.0000000000000561","volume":"109","author":"Artola R.T.","year":"2016","unstructured":"Artola R.T.; Mihos C.G.; Santana O.; Effects of statin therapy in patients with systemic lupus erythematosus. South Med J 2016,109(11),705-711","journal-title":"South Med J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.thromres.2016.12.019","volume":"150","author":"Verdoia M.","year":"2017","unstructured":"Verdoia M.; Pergolini P.; Rolla R.; Nardin M.; Schaffer A.; Barbieri L.; Daffara V.; Marino P.; Bellomo G.; Suryapranata H.; De Luca G.; Novara atherosclerosis study Group (NAS). Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Thromb Res 2017,150,90-95","journal-title":"Thromb Res"},{"key":"ref=52","first-page":"213","volume":"99","author":"Sukpat S.","year":"2016","unstructured":"Sukpat S.; Israsena N.; Patumraj S.; Pleiotropic effects of simvastatin on wound healing in Diabetic Mice. J Med Assoc Thai 2016,99(2),213-219","journal-title":"J Med Assoc Thai"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mvr.2017.01.002","volume":"111","author":"Tun T.","year":"2017","unstructured":"Tun T.; Kang Y.S.; Effects of simvastatin on CAT-1-mediated arginine transport and NO level under high glucose conditions in conditionally immortalized rat inner blood-retinal barrier cell lines (TR-iBRB). Microvasc Res 2017,111,60-66","journal-title":"Microvasc Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pupt.2017.03.001","volume":"44","author":"Rossi A.","year":"2017","unstructured":"Rossi A.; Inciardi R.M.; Rossi A.; Temporelli P.L.; Lucci D.; Gonzini L.; Marchioli R.; Nicolosi G.L.; Tavazzi L.; Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther GISSI-HF Investigators2017,44,16-23","journal-title":"Pulm Pharmacol Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"Oesterle A.","year":"2017","unstructured":"Oesterle A.; Laufs U.; Liao J.K.; Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017,120(1),229-243","journal-title":"Circ Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"l5674","DOI":"10.1136\/bmj.l5674","volume":"367","author":"Byrne P.","year":"2019","unstructured":"Byrne P.; Cullinan J.; Smith S.M.; Statins for primary prevention of cardiovascular disease. BMJ 2019,367,l5674","journal-title":"BMJ"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4103\/2230-8210.163106","volume":"19","author":"Kavalipati N.","year":"2015","unstructured":"Kavalipati N.; Shah J.; Ramakrishan A.; Vasnawala H.; Pleiotropic effects of statins. Indian J Endocrinol Metab 2015,19(5),554-562","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/archneur.62.2.317","volume":"62","author":"Lalani S.R.","year":"2005","unstructured":"Lalani S.R.; Vladutiu G.D.; Plunkett K.; Lotze T.E.; Adesina A.M.; Scaglia F.; Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005,62(2),317-320","journal-title":"Arch Neurol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"Stroes E.S.","year":"2015","unstructured":"Stroes E.S.; Thompson P.D.; Corsini A.; Vladutiu G.D.; Raal F.J.; Ray K.K.; Roden M.; Stein E.; Tokg\u00f6zo\u011flu L.; Nordestgaard B.G.; Bruckert E.; De Backer G.; Krauss R.M.; Laufs U.; Santos R.D.; Hegele R.A.; Hovingh G.K.; Leiter L.A.; Mach F.; M\u00e4rz W.; Newman C.B.; Wiklund O.; Jacobson T.A.; Catapano A.L.; Chapman M.J.; Ginsberg H.N.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015,36(17),1012-1022","journal-title":"Eur Heart J"},{"key":"ref=60","first-page":"427","volume":"3","author":"Meng C.Q.","year":"2002","unstructured":"Meng C.Q.; Ezetimibe. Schering-Plough. Curr Opin Investig Drugs 2002,3(3),427-432","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1124\/dmd.30.4.430","volume":"30","author":"Patrick J.E.","year":"2002","unstructured":"Patrick J.E.; Kosoglou T.; Stauber K.L.; Alton K.B.; Maxwell S.E.; Zhu Y.; Statkevich P.; Iannucci R.; Chowdhury S.; Affrime M.; Cayen M.N.; Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002,30(4),430-437","journal-title":"Drug Metab Dispos"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1309\/5RQ0-JCQU-5XF2-51LQ","volume":"117","author":"van Heek T.","year":"2002","unstructured":"van Heek T.; Rader A.E.; Offerhaus G.J.; McCarthy D.M.; Goggins M.; Hruban R.H.; Wilentz R.E.; K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002,117(5),755-765","journal-title":"Am J Clin Pathol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/jm030283g","volume":"47","author":"Clader J.W.","year":"2004","unstructured":"Clader J.W.; The discovery of ezetimibe: a view from outside the receptor. J Med Chem 2004,47(1),1-9","journal-title":"J Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","volume":"44","author":"Kosoglou T.","year":"2005","unstructured":"Kosoglou T.; Statkevich P.; Johnson-Levonas A.O.; Paolini J.F.; Bergman A.J.; Alton K.B.; Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005,44(5),467-494","journal-title":"Clin Pharmacokinet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","volume":"23","author":"Nutescu E.A.","year":"2003","unstructured":"Nutescu E.A.; Shapiro N.L.; Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003,23(11),1463-1474","journal-title":"Pharmacotherapy"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/VHRM.S33664","volume":"8","author":"Phan B.A.","year":"2012","unstructured":"Phan B.A.; Dayspring T.D.; Toth P.P.; Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012,8,415-427","journal-title":"Vasc Health Risk Manag"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/13543784.11.6.831","volume":"11","author":"Kajinami K.","year":"2002","unstructured":"Kajinami K.; Takekoshi N.; Cholesterol absorption inhibitors in development as potential therapeutics. Expert Opin Investig Drugs 2002,11(6),831-835","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1742-1241.2001.tb11168.x","volume":"55","author":"Miettinen T.A.","year":"2001","unstructured":"Miettinen T.A.; Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. Int J Clin Pract 2001,55(10),710-716","journal-title":"Int J Clin Pract"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2169\/internalmedicine.47.1099","volume":"47","author":"Miura S.","year":"2008","unstructured":"Miura S.; Saku K.; Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008,47(13),1165-1170","journal-title":"Intern Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1194\/jlr.P600009-JLR200","volume":"47","author":"Clarenbach J.J.","year":"2006","unstructured":"Clarenbach J.J.; Reber M.; L\u00fctjohann D.; von Bergmann K.; Sudhop T.; The lipid-lowering effect of ezetimibe in pure vegetarians. J Lipid Res 2006,47(12),2820-2824","journal-title":"J Lipid Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1185\/030079905X28872","volume":"21","author":"Wierzbicki A.S.","year":"2005","unstructured":"Wierzbicki A.S.; Doherty E.; Lumb P.J.; Chik G.; Crook M.A.; Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005,21(3),333-338","journal-title":"Curr Med Res Opin"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1021\/jm970701f","volume":"41","author":"Rosenblum S.B.","year":"1998","unstructured":"Rosenblum S.B.; Huynh T.; Afonso A.; Davis H.R.; Jr.; Yumibe, N.; Clader, J.W.; Burnett, D.A. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypro-pyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 1998,41(6),973-980","journal-title":"J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4065\/80.5.587","volume":"80","author":"Pearson T.A.","year":"2005","unstructured":"Pearson T.A.; Denke M.A.; McBride P.E.; Battisti W.P.; Brady W.E.; Palmisano J.; A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005,80(5),587-595","journal-title":"Mayo Clin Proc"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1185\/030079908X273273","volume":"24","author":"Roeters van Lennep H.W.","year":"2008","unstructured":"Roeters van Lennep H.W.; Liem A.H.; Dunselman P.H.; Dallinga-Thie G.M.; Zwinderman A.H.; Jukema J.W.; The efficacy of statin monotherapy uptitration versus switching to ezetimibe\/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008,24(3),685-694","journal-title":"Curr Med Res Opin"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","volume":"107","author":"Ballantyne C.M.","year":"2003","unstructured":"Ballantyne C.M.; Houri J.; Notarbartolo A.; Melani L.; Lipka L.J.; Suresh R.; Sun S.; LeBeaut A.P.; Sager P.T.; Veltri E.P.; Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation Ezetimibe Study Group2003,107(19),2409-2415","journal-title":"Circulation"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.11622\/smedj.2013031","volume":"54","author":"Padhy B.M.","year":"2013","unstructured":"Padhy B.M.; Yadav R.; Gupta Y.K.; Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. Singapore Med J 2013,54(2),90-95","journal-title":"Singapore Med J"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","volume":"25","author":"Madamanchi N.R.","year":"2005","unstructured":"Madamanchi N.R.; Vendrov A.; Runge M.S.; Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005,25(1),29-38","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1253\/circj.CJ-12-0331","volume":"76","author":"Nochioka K.","year":"2012","unstructured":"Nochioka K.; Tanaka S.; Miura M.; Zhulanqiqige E.; Fukumoto Y.; Shiba N.; Shimokawa H.; Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J 2012,76(8),2023-2030","journal-title":"Circ J"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2125.2007.03080.x","volume":"65","author":"Hussein O.","year":"2008","unstructured":"Hussein O.; Minasian L.; Itzkovich Y.; Shestatski K.; Solomon L.; Zidan J.; Ezetimibe\u2019s effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008,65(5),637-645","journal-title":"Br J Clin Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/FJC.0b013e31821e8cb2","volume":"58","author":"Undas A.","year":"2011","unstructured":"Undas A.; Machnik A.; Potaczek D.P.; Wypasek E.; Zmudka K.; Tracz W.; Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 2011,58(2),167-172","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.phrs.2009.04.011","volume":"60","author":"Nakamura T.","year":"2009","unstructured":"Nakamura T.; Sato E.; Fujiwara N.; Kawagoe Y.; Ueda Y.; Suzuki T.; Ueda S.; Adachi H.; Okuda S.; Yamagishi S.; Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009,60(6),525-528","journal-title":"Pharmacol Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2011.02394.x","volume":"271","author":"Krysiak R.","year":"2012","unstructured":"Krysiak R.; Zmuda W.; Okopien B.; The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012,271(1),32-42","journal-title":"J Intern Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"Chalasani N.","year":"2004","unstructured":"Chalasani N.; Aljadhey H.; Kesterson J.; Murray M.D.; Hall S.D.; Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004,126(5),1287-1292","journal-title":"Gastroenterology"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"Seidah N.G.","year":"2003","unstructured":"Seidah N.G.; Benjannet S.; Wickham L.; Marcinkiewicz J.; Jasmin S.B.; Stifani S.; Basak A.; Prat A.; Chretien M.; The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003,100(3),928-933","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11239-016-1364-1","volume":"42","author":"Latimer J.","year":"2016","unstructured":"Latimer J.; Batty J.A.; Neely R.D.; Kunadian V.; PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis 2016,42(3),405-419","journal-title":"J Thromb Thrombolysis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pharmtox-010716-104944","volume":"57","author":"Burke A.C.","year":"2017","unstructured":"Burke A.C.; Dron J.S.; Hegele R.A.; Huff M.W.; PCSK9: regulation and target for drug development for dyslipidemia. Annu Rev Pharmacol Toxicol 2017,57,223-244","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","volume":"132","author":"Bergeron N.","year":"2015","unstructured":"Bergeron N.; Phan B.A.; Ding Y.; Fong A.; Krauss R.M.; Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015,132(17),1648-1666","journal-title":"Circulation"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11936-017-0556-0","volume":"19","author":"Durairaj A.","year":"2017","unstructured":"Durairaj A.; Sabates A.; Nieves J.; Moraes B.; Baum S.; Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and its inhibitors: a review of physiology, biology, and clinical data. Curr Treat Options Cardiovasc Med 2017,19(8),58","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1074\/jbc.M701634200","volume":"282","author":"Fisher T.S.","year":"2007","unstructured":"Fisher T.S.; Lo Surdo P.; Pandit S.; Mattu M.; Santoro J.C.; Wisniewski D.; Cummings R.T.; Calzetta A.; Cubbon R.M.; Fischer P.A.; Tarachandani A.; De Francesco R.; Wright S.D.; Sparrow C.P.; Carfi A.; Sitlani A.; Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 2007,282(28),20502-20512","journal-title":"J Biol Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","volume":"28","author":"Dron J.S.","year":"2017","unstructured":"Dron J.S.; Hegele R.A.; Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr Opin Lipidol 2017,28(2),161-169","journal-title":"Curr Opin Lipidol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1326-6-30","volume":"6","author":"Reddy S.S.","year":"2011","unstructured":"Reddy S.S.; Connor T.E.; Weeber E.J.; Rebeck W.; Similarities and differences in structure, expression, and functions of VLDLR and ApoER2. Mol Neurodegener 2011,6,30","journal-title":"Mol Neurodegener"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"Dias C.S.","year":"2012","unstructured":"Dias C.S.; Shaywitz A.J.; Wasserman S.M.; Smith B.P.; Gao B.; Stolman D.S.; Crispino C.P.; Smirnakis K.V.; Emery M.G.; Colbert A.; Gibbs J.P.; Retter M.W.; Cooke B.P.; Uy S.T.; Matson M.; Stein E.A.; Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012,60(19),1888-1898","journal-title":"J Am Coll Cardiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"Sullivan D.","year":"2012","unstructured":"Sullivan D.; Olsson A.G.; Scott R.; Kim J.B.; Xue A.; Gebski V.; Wasserman S.M.; Stein E.A.; Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012,308(23),2497-2506","journal-title":"JAMA"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11883-017-0684-8","volume":"19","author":"El Khoury P.","year":"2017","unstructured":"El Khoury P.; Elbitar S.; Ghaleb Y.; Khalil Y.A.; Varret M.; Boileau C.; Abifadel M.; PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to Anti-PCSK9 therapies. Curr Atheroscler Rep 2017,19(12),49","journal-title":"Curr Atheroscler Rep"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano R.P.","year":"2012","unstructured":"Giugliano R.P.; Desai N.R.; Kohli P.; Rogers W.J.; Somaratne R.; Huang F.; Liu T.; Mohanavelu S.; Hoffman E.B.; McDonald S.T.; Abrahamsen T.E.; Wasserman S.M.; Scott R.; Sabatine M.S.; Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet LAPLACE-TIMI 57 Investigators2012,380(9858),2007-2017","journal-title":"Lancet"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"Koren M.J.","year":"2012","unstructured":"Koren M.J.; Scott R.; Kim J.B.; Knusel B.; Liu T.; Lei L.; Bolognese M.; Wasserman S.M.; Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012,380(9858),1995-2006","journal-title":"Lancet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal F.","year":"2012","unstructured":"Raal F.; Scott R.; Somaratne R.; Bridges I.; Li G.; Wasserman S.M.; Stein E.A.; Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012,126(20),2408-2417","journal-title":"Circulation"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejim.2016.10.009","volume":"38","author":"He X-X.","year":"2017","unstructured":"He X-X.; Zhang R.; Zuo P-Y.; Liu Y-W.; Zha X-N.; Shan S-S.; Liu C-Y.; The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis. Eur J Intern Med 2017,38,52-60","journal-title":"Eur J Intern Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Giugliano R.P.; Keech A.C.; Honarpour N.; Wiviott S.D.; Murphy S.A.; Kuder J.F.; Wang H.; Liu T.; Wasserman S.M.; Sever P.S.; Pedersen T.R.; Committee F.S.; FOURIER steering committee and investigators. evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017,376(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000946","volume":"3","author":"Bellera N.","year":"2014","unstructured":"Bellera N.; Barba I.; Rodriguez-Sinovas A.; Ferret E.; As\u00edn M.A.; Gonzalez-Alujas M.T.; P\u00e9rez-Rodon J.; Esteves M.; Fonseca C.; Toran N.; Garcia Del Blanco B.; P\u00e9rez A.; Garc\u00eda-Dorado D.; Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling. J Am Heart Assoc 2014,3(5)","journal-title":"J Am Heart Assoc"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nm1582","volume":"13","author":"Car\u00e8 A.","year":"2007","unstructured":"Car\u00e8 A.; Catalucci D.; Felicetti F.; Bonci D.; Addario A.; Gallo P.; Bang M.L.; Segnalini P.; Gu Y.; Dalton N.D.; Elia L.; Latronico M.V.; H\u00f8ydal M.; Autore C.; Russo M.A.; Dorn G.W.; Ellingsen O.; Ruiz-Lozano P.; Peterson K.L.; Croce C.M.; Peschle C.; Condorelli G.; MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007,13(5),613-618","journal-title":"Nat Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Stein E.A.; Dufour R.; Turner T.; Civeira F.; Burgess L.; Langslet G.; Scott R.; Olsson A.G.; Sullivan D.; Hovingh G.K.; Cariou B.; Gouni-Berthold I.; Somaratne R.; Bridges I.; Scott R.; Wasserman S.M.; Gaudet D.; Investigators R.; PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet RUTHERFORD-2 Investigators2015,385(9965),331-340","journal-title":"Lancet"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"Robinson J.G.","year":"2014","unstructured":"Robinson J.G.; Nedergaard B.S.; Rogers W.J.; Fialkow J.; Neutel J.M.; Ramstad D.; Somaratne R.; Legg J.C.; Nelson P.; Scott R.; Wasserman S.M.; Weiss R.; Investigators L.; Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA LAPLACE-2 Investigators2014,311(18),1870-1882","journal-title":"JAMA"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4997\/JRCPE.2017.212","volume":"47","author":"Hadjiphilippou S.","year":"2017","unstructured":"Hadjiphilippou S.; Ray K.K.; Evolocumab and clinical outcomes in patients with cardiovascular disease. J R Coll Physicians Edinb 2017,47(2),153-155","journal-title":"J R Coll Physicians Edinb"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3949\/ccjm.84.s4.01","volume":"84","author":"Nissen S.E.","year":"2017","unstructured":"Nissen S.E.; Nicholls S.J.; Results of the GLAGOV trial. Cleve Clin J Med 2017,84(12)(Suppl. 4),e1-e5","journal-title":"Cleve Clin J Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.jacc.2019.07.087","volume":"74","author":"Chapman M.J.","year":"2019","unstructured":"Chapman M.J.; Ginsberg H.N.; Evolocumab treatment of hypercholesterolemia in OSLER-1: enduring efficacy, tolerability, and safety over 5 years. J Am Coll Cardiol 2019,74(17),2147-2149","journal-title":"J Am Coll Cardiol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Honarpour N.; Blom D.J.; Hovingh G.K.; Xu F.; Scott R.; Wasserman S.M.; Stein E.A.; Investigators T.; Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet TESLA Investigators2015,385(9965),341-350","journal-title":"Lancet"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/00003495-199651030-00011","volume":"51","author":"Plosker G.L.","year":"1996","unstructured":"Plosker G.L.; Wagstaff A.J.; Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia Drugs 1996,51(3),433-459","journal-title":"Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia Drugs"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200505091738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181653\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200505091738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T18:22:36Z","timestamp":1696098156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181653\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200505091738","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}